YCBD earnings analysis
What we found in YCBD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied filing text does not include the current-period income statement, balance sheet, cash-flow statement, segment data or MD&A results, so revenue, margins, EPS and free cash flow cannot be reported reliably here. The filing does document $61,990 of gross proceeds from issuing 100,000 ELOC shares, supporting liquidity but increasing dilution risk. Management reported effective disclosure controls, no material internal-control changes and no material pending litigation; risk factors were unchanged from the 2025 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- ELOC Provides $61,990 of Financing
- The company issued 100,000 common shares under its ELOC for gross proceeds of $61,990, providing additional financing during the quarter.
- Disclosure Controls Deemed Effective
- Management concluded that disclosure controls and procedures were effective as of the end of the reporting period, with reasonable assurance over required reporting and communication.
- No Material Control Changes
- The company reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the most recent fiscal quarter.
- No Material Pending Litigation
- Management stated that it was not a party to any pending legal proceedings expected to have a material adverse effect on the business, financial condition, or results of operations.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Equity Financing and Dilution
- The issuance of 100,000 common shares for $61,990 under the ELOC creates additional equity dilution and indicates continued reliance on capital-market financing.
- Existing 2025 10-K Risks Remain
- The filing states that there have been no material changes from the risk factors in the 2025 10-K, so the existing risks—including liquidity, accumulated losses, regulatory pressures and operating losses—remain applicable.
- Potential Ordinary-Course Legal Exposure
- Although no material legal proceedings were identified, the company disclosed that it may become involved in ordinary-course legal proceedings and referred investors to Note 10 for commitments and contingencies.
What they said about what is next.
No quantitative outlook or forward guidance is included in the supplied filing text; outlook appears deferred to the earnings press release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- cbdMD, Inc. reported an increase in revenues to $5.64 million for Q2 2026, a year-over-year growth of 19%, while gross profit margins decreased to 57.7%. The company experienced a reduced net loss for the quarter of…
- 10-Q · February 17, 2026
- cbdMD reported Q1 (period ended Dec 31, 2025) net sales of $5,016,904 and GAAP loss per share of $(0.04). Liquidity improved materially with cash of $3,387,933 (up $1,126,691 QoQ) following preferred stock proceeds of…
- 10-K · December 19, 2025
- cbdMD's FY2025 10-K describes a business stabilizing revenues while cutting GAAP operating losses (from $3.3M in FY2024 to $2.1M in FY2025) and simplifying its capital structure through conversion of preferred stock.…
- 10-Q · August 14, 2025
- cbdMD reported Q3 net sales of $4,606,796, down from $5,173,878 a year earlier, with gross margin of 61.5% and a wider loss from operations of $(904,686). Reported GAAP loss per share improved to $(0.21) (basic and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing YCBD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever